Hsp70-Hsp90 organising protein (HOP/STIP1) is required for KSHV lytic replication
Kaposi's sarcoma-associated herpesvirus (KSHV) is a DNA virus that causes Kaposi's sarcoma, a cancer of endothelial origin. KSHV uses the activity of host molecular chaperones like Hsp70 and Hsp90 for the folding of host and viral proteins required for productive infection. Hsp70 and Hsp90 chaperones form proteostasis networks with several regulatory proteins known as co-chaperones. Of these, Hsp90-Hsp70-organizing protein (HOP) is an early-stage co-chaperone that regulates the transfer of folding substrate proteins between the Hsp70 and Hsp90 chaperone systems. While the roles for Hsp90 and Hsp70 in KSHV biology have been described, HOP has not previously been studied in this context despite its prominent interaction with both chaperones. Here, we demonstrate a novel function for HOP as a new host factor required for effective lytic replication of KSHV in primary effusion cell lines.
Authors
- Michael Okpara (ORCID: https://orcid.org/0000-0001-9683-5990)
- Adrienne L. Edkins (ORCID: https://orcid.org/0000-0002-3615-6651)
- Abir Chakraborty (ORCID: https://orcid.org/0000-0002-3131-0808)
- Adrian Whitehouse (ORCID: https://orcid.org/0000-0003-3866-7110)
- Zoè Jackson
- Clinton G. L. Veale (ORCID: https://orcid.org/0000-0002-4043-7106)
- Elisa Kirigin (ORCID: https://orcid.org/0000-0003-2606-6297)
- Frederick Weaver
- Lorraine Matandirotya (ORCID: https://orcid.org/0000-0003-3975-489X)
- Jamie-Lee Ruck
Institutions
- University of Leeds (GB)
- University of Cape Town (ZA)
- Rhodes University (ZA)
Publication Details
- Journal
- Journal of General Virology
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1099/jgv.0.002053
- Citations
- 2
- Primary Topic
- Vector-borne infectious diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.03
Funders
- Academy of Medical Sciences
- University of Leeds
- National Research Foundation
- Rhodes University
- Foreign, Commonwealth and Development Office
- Medical Research Council
- European and Developing Countries Clinical Trials Partnership